innovateupstate.org Open in urlscan Pro
67.43.0.50  Public Scan

Form analysis
1 forms found in the DOM

POST /home/SearchForm/

<form id="Form_SearchForm" action="/home/SearchForm/" method="POST" enctype="application/x-www-form-urlencoded">
  <div id="Form_SearchForm_error" class="form__message alert alert- message " style="display: none"></div>
  <fieldset class="form__fieldset">
    <legend class="form__legend">Search Innovate Upstate Website</legend>
    <div id="Form_SearchForm_q_Holder" class="form__field field text">
      <label class="field__label field__label-left left" for="Form_SearchForm_q">Search ...</label>
      <div class="field__content middleColumn">
        <input type="text" name="q" class="text form-control" id="Form_SearchForm_q" required="required" aria-required="true" placeholder="Search ...">
      </div>
    </div>
    <input type="hidden" name="SecurityID" value="214c1898f6dc3e7a8364fd830af23e022c9ebcf1" class="hidden" id="Form_SearchForm_SecurityID">
    <div class="clear"><!-- --></div>
  </fieldset>
  <div class="form__actions btn-toolbar">
    <button type="submit" name="action_doSearch" value="Find it!" class="action btn-secondary btn btn-primary" id="Form_SearchForm_action_doSearch">
      <svg class="svg-inline--fa fa-search fa-w-16" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="search" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" data-fa-i2svg="">
        <path fill="currentColor"
          d="M505 442.7L405.3 343c-4.5-4.5-10.6-7-17-7H372c27.6-35.3 44-79.7 44-128C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c48.3 0 92.7-16.4 128-44v16.3c0 6.4 2.5 12.5 7 17l99.7 99.7c9.4 9.4 24.6 9.4 33.9 0l28.3-28.3c9.4-9.4 9.4-24.6.1-34zM208 336c-70.7 0-128-57.2-128-128 0-70.7 57.2-128 128-128 70.7 0 128 57.2 128 128 0 70.7-57.2 128-128 128z">
        </path>
      </svg><!-- <i class="fas fa-search"></i> Font Awesome fontawesome.com --><span class="sr-only">Search</span>
    </button>
  </div>
</form>

Text Content

Please, enable javascript!




Assisting Industry to Develop, Test and Prove Ideas.
The Internet connection is missing right now, but you're able to browse
previously opened pages offline.
Please, enable javascript.

Innovate Upstate Assisting Industry to Develop, Test and Prove Ideas.
Home (current)
About About
Innovate Upstate News
Innovate Upstate Quarterly

Collaborative Research
Engage With an Expert
Commercialize Technology
Utilize Core Facilities
CNY Biotech Accelerator
Contact Us
Search

Search Innovate Upstate Website
Search ...


Search


HOME

Tell us about your project »


CENTRAL NEW YORK’S FOREMOST FACULTY, STUDENTS AND STAFF ARE AVAILABLE TO HELP
YOUR BUSINESS INNOVATE.

Tell us about your project »
COMMERCIALIZE TECHNOLOGY


With the resources of the SUNY Research Foundation, and our history of
successful partnerships, we are here to help move biomedical products and ideas
to market.

LEARN MORE
LEARN MORE
ENGAGE WITH AN EXPERT


Our scientists and core facilities can help move discoveries into practice and
technologies into the marketplace.

MEET THE TEAM
MEET THE TEAM
UTILIZE CORE FACILITIES


Upstate is home to top research facilities with highly specialized equipment and
advanced instrumentation, to support research and product development.

VIEW
COLLABORATIVE RESEARCH


We are here to create the relationships and partnerships needed to move
innovative ideas forward.

LET'S GET STARTED
LET'S GET STARTED


VIEW ALL TECH RECENT TECH FROM SUNY UPSTATE

Small Molecule Inhibitors for Alzheimer's Immunotherapy
January 11, 2023

Pan-SHIP1/2 inhibitors enhance phagocytosis of dead neurons and amyloid beta by
microglia. Backgrou...

Pan-SHIP1/2 inhibitors enhance phagocytosis of dead neurons and amyloid beta by
microglia. Background: The beta-amyloid (1-42) peptide fragment is a crucial
component of beta-amyloid debris that forms plaques in Alzheimer's Disease,
playing a significant role in disease pathology and cognitive decline. Increased
amyloid deposits and tau tangles exert chronic stress on microglia, leading to
the emergence of "dark microglia" associated with pathological processes in
Alzheimer's, including production of inflammatory cytokines, neurocytotoxicity,
loss of neuronal synapses, and promotion of neuro-fibrillary tau tangles.
However, microglia also have substantial homeostatic functions in the brain,
which include pruning of synapses or phagocytic clearance of dead cells, cell
debris, and beta-amyloid deposits. Technology Overview: The newly developed
small molecule pan-SHIP1/2 inhibitors can modulate microglia activity in
vivo, enhancing basal microglial homeostatic functions for therapeutic purposes
in Alzheimer's disease. Specifically, the inhibitors, which were shown to be
bioavailable in the central nervous system (CNS) in a mouse model, significantly
increase phagocytosis of dead neurons and amyloid beta by microglia both in
vitro and in vivo. The ability of these compounds to increase microglial and
myeloid cell numbers in the CNS, while enhancing their capacity to remove
beta-amyloid deposits, suggests that they could be used to reduce or reverse
cognitive decline in Alzheimer's patients. Advantages: - Bioavailability in the
CNS
- Immunotherapeutic approach Applications: - Alzheimer’s disease - Other
dementias Intellectual Property Summary: Patent application submitted,

 * PCT/US2019/044476 Methods of activating microglial cells 
 * EP3829589 Methods of activating microglial cells
 * AU2019314405 Methods of activating microglial cells 
 * CA3107823 Methods of activating microglial cells 
 * U.S. 17/262,784 Methods of activating microglial cells

Licensing Potential: Development partner, Commercial partner, Licensing, Seeking
investment Licensing Status: This technology is available for licensing.
https://suny.technologypublisher.com/files/sites/istock-513688464.jpg  



Human Trabecular Organ-on-a-Chip Models
January 06, 2023

3D biomimetic hydrogel models of the trabecular meshwork of the eye, and a
bioengineered system for ...

3D biomimetic hydrogel models of the trabecular meshwork of the eye, and a
bioengineered system for modelling the conventional outflow tract. Background:
Models of the trabecular meshwork have largely been 2D up until now, but
research has shown that 2D models of the TM behave differently -- sometimes in
complete opposition -- to 3D models. A 3D model better approximates the actual
anatomy of the human tissue, permits more sophisticated experiments, and
provides increased accuracy in data-gathering and therapy production to
researchers. This trend applies to other models of the eye as well. Technology
Overview: This technology is a 3D biomimetic hydrogel model of the trabecular
meshwork (TM) of the eye, located on a microfluidics chip, intended to be used,
for example, to study the relation between the mechanotransduction of the
YAP/TAZ proteins and stiffening of the TM cells and extracellular matrix.
Stiffening of the TM is associated with primary open angle glaucoma, the most
common form of glaucoma. Figure 1 - Complete TM-on-a-chip setup Stage of
Development: Technology Readiness Level (TRL) 3 - Analytical and experimental
critical function and/or characteristic proof of concept. Bioengineered Human
Trabecular Meshwork for Biological Applications This technology is "a system for
modeling the conventional outflow tract." Also provided is a method for using
the system for screening by contacting the cells with a known or suspected
medicament and measuring its effects on the system such as flow of a perfusate.
Also provided is a method of making the system by fabricating the porous
substrate as a micropatterned scaffold. Figure 2 - An artistic rendering of a
bi-layered "artificial TM"  Advantages: These two technologies more accurately
approximate human 3D tissue anatomy with focus on the cell-ECM interface, and
will permit more sophisticated research, clinically relevant drug screening and
therapeutic testing, increased accuracy in data-gathering and drug production.
Applications: Organ on a chip market and pharmaceutical testing for the eye.
Intellectual Property Summary: Patent application submitted, Provisional
63/059,965 filed 7/31/20 US 16/044,806  Stage of Development: Technology
Readiness Level (TRL) 6 - System/subsystem model or prototype demonstration in a
relevant environment. Licensing Potential: Licensing, Commercial partner,
Development partner Licensing Status: These technologies from SUNY Upstate
Medical University and SUNY Polytechnic Institute respectively are available for
licensing.
https://suny.technologypublisher.com/files/sites/adobestock_94313718_(1).jpeg  

A Nanotrap to Improve Survival in Severe Sepsis by Attenuating Hyperinflammation
Through Hemoperfusion
September 15, 2022

This optimized nanotrap therapy in combination with a moderate antibiotic
treatment resulted in a 10...

This optimized nanotrap therapy in combination with a moderate antibiotic
treatment resulted in a 100% survival rate in severe septic mice.  Background:
The mortality rates in severe sepsis patients are 3041%. In the U.S. alone, 1.7
million people develop sepsis on a yearly basis. Effective therapies to prevent
or treat the cytokine storm or septic shock that often leads to mortality are
lacking, with single mediator targets failing. With current treatments,
conventional adsorption resins are made of hydrophobic polymers for nonspecific
adsorption of biomolecules, for example, Cytosorb® for multiple cytokine
adsorption. However, the spectrum of molecular adsorption in these cartridges is
fixed by the chemistry of the resin, which appears insufficient in clinical
trials. The management of hyperinflammatory reactions is as important as
effective infection control in bacteremia sepsis, which is even critical for
viral sepsis, given no effective antiviral drugs. The precise immune modulation
is critical for sepsis treatment because of the dynamic and dysregulated immune
system in patients Technology Overview:  
 In contrast to conventional absorption resins, researchers at SUNY Upstate
Medical University have developed a hydrophilic, inert, and antifouling
PEG-based PEGA resin for immobilization of versatile telodendrimer (TD) nanotrap
(NT), which avoids cell adhesion. Researchers have discovered that the
immobilization of TD-NTs in size-exclusive hydrogel resins simultaneously
adsorbs septic molecules, e.g. lipopolysaccharides (LPS), cytokines and damage-
or pathogen-associated molecular patterns (DAMPs/PAMPs) from blood with high
efficiency (92–99%). Distinct surface charges displayed on the majority of
pro-inflammatory cytokines (negative) and anti-inflammatory cytokines (positive)
allow for the selective capture via TD NTs with different charge moieties. The
efficacy of NT therapies in murine sepsis is both time-dependent and
charge-dependent.  
https://suny.technologypublisher.com/files/sites/110-2025.jpeg Advantages:  
 This nanotrap technology is particularly effective for gram negative bacteria
caused sepsis which makes up 50% of most sepsis cases. Providing efficient
protein encapsulation with multiple charges and hydrophobic moieties on the
dendritic periphery, the welldefined lineardendritic telodendrimer nanoplatform
has precise and engineerable chemical structures for customized nanocarrier
design in drug delivery. The 'octopus like' structure can be tailored in design,
shape, structure and density based on the makeup of the lipopolysaccharide
(LPS), enabling more efficient binding. Once put back into the body, the TD
nanotrap will trigger the release of microphages to fight the rest of the
infection, reduce swelling, and treat cytokine storm. Applications:  
 For treatment of sepsis caused by virus or bacteria.  Intellectual Property
Summary:
https://patents.google.com/patent/WO2019051121A1/en?q=Compositions+Devices+Removal+Endotoxins+Cytokines&inventor=Juntao+Luo&oq=Juntao+Luo+Compositions+and+Devices+for+Removal+of+Endotoxins+and+Cytokines
  Stage of Development:


 * The combination of the optimized NT therapy with a moderate antibiotic
   treatment resulted in a 100% survival rate in severe septic mice by
   controlling both infection and hyperinflammation, comp only 50–60% with the
   individual therapies. Cytokine analysis, inflammatory gene activation and
   tissue histopathology strongly support the survival benefits of treatments.
 * https://en.wikipedia.org/wiki/Technology_readiness_level

Additional Information:  
https://www.nature.com/articles/s41467-020-17153-0  
 



Antibody Against Inositol 1,4,5-Trisphosphate Receptor Type 2 (anti-IP3R
antibody)
June 22, 2022

Antibody against the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type
2  Background: The inos...

Antibody against the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type
2  Background: The inositol 1,4,5-trisphosphate receptor type 2 (IP3R2) is an
intracellular Ca²-release channel located on the endoplasmic reticulum (ER).
IP3R2 is characterized by a high sensitivity to both IP3 and ATP and is
biphasically regulated by Ca². Furthermore, IP3R2 is modulated by various
protein kinases. In addition to its regulation by protein kinase A, IP3R2 forms
a complex with adenylate cyclase 6 and is directly regulated by cAMP. Finally,
in the ER, IP3R2 is less mobile than the other IP3R isoforms, while its
functional properties appear dominant in heterotetramers. Technology Overview:  
Antibody against the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type 2
Polyclonal, affinity-purified.
 https://suny.technologypublisher.com/files/sites/2011-110.pngApplications:   

 * Western blot 
 * ELISA \Immunoprecipitation
 * Immunofluorescence assays  

 



Tweets by @InnovateUpstate View on Twitter
Are you at @SCOPEsummit ? Come learn what Upstate has to offer to help conduct
#clinicalresearch and assist biotech… https://t.co/ESZtarRUDQ
RT @of_suny: The Charles R. Ross Memorial Student Research Day is on Wednesday,
March 29th, 2023. #sunyupstateresearchday #sunyupstateresea…
RT @UMUcareers: Position Alert!Project Manager for a large multi-site clinical
trial where Clinical Site is also Coordination Center for th…
RT @UpstateNews: .@SUNY Upstate Radiology Professor David Lubin, MD traveled to
Ukraine last month to deliver trauma first aid supplies to…
February is American Heart Month, and here at Upstate we’re so proud of the work
being done to better understand th… https://t.co/Hi0RtPjmCE
RT @sherberg128: We are looking a for a postdoc! Check out the ad below. Please
retweet to enhance visibility. Thx https://t.co/YsYPNL9nGW

Nurses may be the best equipped to ask and help answer questions about hospital
function and patient care; so how d… https://t.co/YmXmQuOLP5
“It allows patients a real choice, understanding that there may be some
differences in side effects... now they kno… https://t.co/OGQUeFCJek
RT @RogerWongPhD: Is sleep associated w/ dementia risk? Find out in my new
@AmJPrevMed publication with an @UpstateDPHPM MPH student. Key f…
We're Hiring! Looking for a seasoned HRPP professional to lead our program.
Click below to learn more about becomin… https://t.co/fuXS9XGAxN
Pediatric gastroenterologist Prateek Wali, MD, the director of the pediatric IBD
program at the Upstate Golisano Ch… https://t.co/lSfLmnPjQ9
UPDATED: Check out the current list of available funding opportunities here-
https://t.co/pJ8FpkwuZH https://t.co/7sMf5sPzoa

"RSV is the number one reason why infants and young children are hospitalized...
across the world" Listen to SUNY U… https://t.co/FoMUFuK7nt
Upstate student presents research on medical equity and justice on MLK Jr. Day-
https://t.co/Gt9sInUwwB
SUNY Upstate researchers had a paper published this week in @NeuroCellPress on
empathy loss in #dementia; they foun… https://t.co/FDK8cynBhK
“What we say in our lab is, ‘If you can’t communicate your findings to children,
then you haven’t understood it you… https://t.co/kyrVetbAtY
Congrats to Dr. Spencer on his award from the E. Matilda Ziegler Foundation for
the Blind! He's studying the role e… https://t.co/khgn0iZ77C
Check out some of the impressive work our students are doing! MD/PhD student
Akshay Patel in @andras_perl 's lab wi… https://t.co/8RDRmAQxOR
RT @RogerWongPhD: Super happy my @UpstateDPHPM #MPH student published her first,
first-authored paper from my #biostatistics course. Her fi…
IN THE NEWS: “Research is my passion... My mom told me, 'why don't you go and
treat patients?' I said, 'I'm going t… https://t.co/SSIIyDWt44


--------------------------------------------------------------------------------


Copyright © 2023 Innovate Upstate All rights reserved.
Innovate Upstate